Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.

@article{Linthorst2004EnzymeTF,
  title={Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta.},
  author={Gabor E. Linthorst and Carla E. M. Hollak and Wilma E. Donker-Koopman and Anneke Strijland and Johannes M. F. G. Aerts},
  journal={Kidney international},
  year={2004},
  volume={66 4},
  pages={1589-95}
}
BACKGROUND Fabry disease is an X-linked inherited disorder that is caused by excessive lysosomal globotriaosylceramide (CTH) storage due to a deficiency in alpha-galactosidase A (alpha-Gal A). Two recombinant enzyme preparations have been approved as treatment modality. We studied emergence and properties of alpha-Gal A antibodies in treated patients. METHODS During the first 6 to 12 months of intravenous administration of recombinant enzymes (rh-alpha-Gal A) formation of antibodies was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 91 extracted citations

Similar Papers

Loading similar papers…